Avalo Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $192 | $249 |
Gross Profit | -134 | 0 | 105 | 963 |
EBITDA | -20,615 | -14,534 | -13,243 | -12,827 |
EBIT | -20,749 | -14,669 | -13,311 | -12,861 |
Net Income | -20,765 | -13,149 | -35,339 | 23,037 |
Net Change In Cash | 0 | 0 | 192 | 249 |
Free Cash Flow | -11,390 | -9,457 | -15,044 | -11,527 |
Cash | 42,310 | 125,046 | 134,546 | 81,858 |
Basic Shares | 10,829 | 10,514 | 10,471 | 10,784 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $441 | $1,924 | $18,051 | $5,398 |
Gross Profit | 807 | 640 | 14,617 | 3,907 |
EBITDA | -68,343 | -23,286 | -37,294 | -80,497 |
EBIT | -68,512 | -23,444 | -37,460 | -82,154 |
Net Income | -35,129 | -31,544 | -41,658 | -84,349 |
Net Change In Cash | 441 | 1,924 | 18,051 | 5,398 |
Free Cash Flow | -49,056 | -30,838 | -26,846 | -71,005 |
Cash | 134,546 | 7,415 | 13,172 | 54,585 |
Basic Shares | 10,784 | 277 | 39 | 36 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$1.92 |
2025-03-31 | -$1.28 |
2024-12-31 | -$2.74 |
2024-09-30 | -$1.25 |
